News Column

Findings from S.X. Xu and Colleagues Update Understanding of Cancer Therapy (Sustained release of PTX-incorporated nanoparticles synergized by burst...

September 10, 2014



Findings from S.X. Xu and Colleagues Update Understanding of Cancer Therapy (Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX.HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor ...)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news originating from Tianjin, People's Republic of China, by NewsRx correspondents, research stated, "As drug therapies become increasingly sophisticated, the synergistic benefits of two or more drugs are often required. In this study, we aimed at improving anti-tumor efficiency of paclitaxel (PTX)-incorporated thermo-sensitive injectable hydrogel by the synergy of burst release of doxorubicin hydrochloride (DOX-HCl)."

Our news journalists obtained a quote from the research, "Thermosensitive injectable hydrogel composed of nanoparticles assembled from amphiphilic copolymer poly(epsilon-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone)-poly(ethylene glycol)-poly(scaprolaone-co-1,4,8-trioxa[4.6]spiro-9-undecanone) (PECT) was fabricated. Hydrophobic PTX and hydrophilic DOX.HCl were loaded simultaneously in the thermo-sensitive injectable hydrogel by a two-stage entrapment. Thermosensitive gelling behaviors of drug-loading PECT nanoparticle aqueous dispersions were studied. In vitro release profiles of PTX and DOX.HCl and in vivo anti-tumor effect by dual drugs from PECT hydrogel were investigated. The results showed that hydrophilic and hydrophobic drugs could be successfully entrapped in PECT hydrogel simultaneously without affecting its thermo-sensitive behavior. In vitro release profiles demonstrated the burst release of DOX.HCl and the sustained release of PTX. Antitumor effect was improved by a fast and tense attack caused by the burst release of hydrophilic DOX'HCI from hydrogel, which was continued by the sequent sustained release of PTX-incorporated nanoparticles and remnant DOX.HCl."

According to the news editors, the research concluded: "Unintentionally, entrapped in PECT hydrogel, hydrophilic DOX.HCl was observed to have a sustained releasing pattern in vitro and in vivo."

For more information on this research see: Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX.HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency. European Journal of Pharmaceutical Sciences, 2014;62():267-273. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutical Sciences - www.elsevier.com/wps/product/cws_home/523997)

The news correspondents report that additional information may be obtained from S.X. Xu, Collaborat Innovat Center Chem Sci & Engn Tianjin, Tianjin 300072, People's Republic of China. Additional authors for this research include W.W. Wang, X.J. Li, J.P. Liu, A.J. Dong and L.D. Deng (see also Oncology).

Keywords for this news article include: Tianjin, People's Republic of China, Asia, Alcohols, Emerging Technologies, Hydrogel, Nanoparticle, Nanotechnology, Oncology, Organic Chemicals, Polyethylene Glycols, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters